KR0168649B1 - 비스(3,5-디-알킬-4-히드록시페닐티오)메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물 - Google Patents

비스(3,5-디-알킬-4-히드록시페닐티오)메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물 Download PDF

Info

Publication number
KR0168649B1
KR0168649B1 KR1019910010091A KR910010091A KR0168649B1 KR 0168649 B1 KR0168649 B1 KR 0168649B1 KR 1019910010091 A KR1019910010091 A KR 1019910010091A KR 910010091 A KR910010091 A KR 910010091A KR 0168649 B1 KR0168649 B1 KR 0168649B1
Authority
KR
South Korea
Prior art keywords
hypertriglyceridemia
methane
hydroxyphenylthio
pharmaceutical composition
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019910010091A
Other languages
English (en)
Korean (ko)
Other versions
KR920000327A (ko
Inventor
젠 탄 마오 사이몬
쿠 죠지
리 잭슨 리챠드
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼스 인크. filed Critical 게리 디. 스트리트
Publication of KR920000327A publication Critical patent/KR920000327A/ko
Application granted granted Critical
Publication of KR0168649B1 publication Critical patent/KR0168649B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019910010091A 1990-06-19 1991-06-18 비스(3,5-디-알킬-4-히드록시페닐티오)메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물 Expired - Fee Related KR0168649B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US540,657 1990-06-19
US07/540,657 US5122542A (en) 1990-06-19 1990-06-19 Hypotriglyceridemic use of certain bis (3,5-di-alkyl-4-hydroxyphenylthio)methanes

Publications (2)

Publication Number Publication Date
KR920000327A KR920000327A (ko) 1992-01-29
KR0168649B1 true KR0168649B1 (ko) 1999-01-15

Family

ID=24156398

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910010091A Expired - Fee Related KR0168649B1 (ko) 1990-06-19 1991-06-18 비스(3,5-디-알킬-4-히드록시페닐티오)메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물

Country Status (13)

Country Link
US (1) US5122542A (OSRAM)
EP (1) EP0462556B1 (OSRAM)
JP (1) JPH04230213A (OSRAM)
KR (1) KR0168649B1 (OSRAM)
AT (1) ATE129151T1 (OSRAM)
AU (1) AU640486B2 (OSRAM)
DE (1) DE69113871T2 (OSRAM)
DK (1) DK0462556T3 (OSRAM)
ES (1) ES2080854T3 (OSRAM)
GR (1) GR3018351T3 (OSRAM)
IE (1) IE69315B1 (OSRAM)
TW (1) TW205542B (OSRAM)
ZA (1) ZA914538B (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063408A1 (en) * 2004-12-17 2006-06-22 Stocker Ronald O Compositions and methods for treating cardiovascular disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734527A (en) * 1986-10-17 1988-03-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol
US4954528A (en) * 1988-12-08 1990-09-04 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic use of bis(3,5-di-tertiary-butly-4-hydroxyphenylthio)methane
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US4959392A (en) * 1989-07-24 1990-09-25 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus

Also Published As

Publication number Publication date
DE69113871D1 (de) 1995-11-23
DK0462556T3 (da) 1995-11-27
AU7836591A (en) 1992-01-02
JPH04230213A (ja) 1992-08-19
IE912087A1 (en) 1992-01-01
EP0462556A2 (en) 1991-12-27
TW205542B (OSRAM) 1993-05-11
EP0462556A3 (en) 1992-03-11
ATE129151T1 (de) 1995-11-15
AU640486B2 (en) 1993-08-26
KR920000327A (ko) 1992-01-29
IE69315B1 (en) 1996-09-04
ZA914538B (en) 1992-03-25
ES2080854T3 (es) 1996-02-16
GR3018351T3 (en) 1996-03-31
EP0462556B1 (en) 1995-10-18
US5122542A (en) 1992-06-16
DE69113871T2 (de) 1996-04-04

Similar Documents

Publication Publication Date Title
KR0150631B1 (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
JP2963556B2 (ja) 抗アテロ−ム性動脈硬化症剤としての新規な２，６−ジ−アルキル−４−シリル−フェノ−ル類
US5128148A (en) Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient
CN1092517C (zh) 利用2,6－二烷基－4－甲硅烷基－苯酚降低血清胆固醇水平的方法
NL8602933A (nl) Geneesmiddel voor het behandelen van dementie.
JP2963557B2 (ja) 抗アテロ−ム性動脈硬化症剤としての新規なビス［４−（２，６−ジ−アルキル）フェノ−ル］シラン誘導体類
KR0168649B1 (ko) 비스(3,5-디-알킬-4-히드록시페닐티오)메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물
US6417231B1 (en) Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
KR900006993B1 (ko) 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온
JP2889663B2 (ja) 真性糖尿病の処置法
KR100205264B1 (ko) 지질 대사 개선 조성물
US4954528A (en) Hypocholesterolemic use of bis(3,5-di-tertiary-butly-4-hydroxyphenylthio)methane
JPH10203974A (ja) 膵リパーゼ活性阻害剤、機能性食品及び食品添加物
EP0149847A2 (en) Therapeutic and preventive agent containing dolichol
KR100496019B1 (ko) 혈당 저하 효과를 가지는 감마 오리자놀
EP0504807B1 (en) Use of bis-(p-hydroxyphenylthio)methane derivatives to inhibit progressive development of insulin-dependent diabetes mellitus
JPS5843385B2 (ja) シジミの薬効成分及びその製造法
JP3886598B2 (ja) 発癌抑制剤
US4151281A (en) Medicinal preparation for the treatment of collagenoses of a rheumatoid nature
KR20180042140A (ko) 은행종자 추출물을 포함하는 혈행개선 및 비만 치료용 조성물
US20020045776A1 (en) Amino thioxomethyl amino oxyacetic acid derivatives

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20011008

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20011008

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000